Fung Simon Fung Fee, Warren Graham W, Singh Anurag K
Department of Radiation Medicine, Roswell Park Cancer Institute, University at Buffalo School of Medicine, Elm and Carlton Streets, Buffalo, New York, 14263, USA.
J Carcinog. 2012;11:20. doi: 10.4103/1477-3163.105340. Epub 2012 Dec 31.
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality. The majority of patients present with advanced (stage III-IV) disease. Such patients are treated with a variety of therapies including surgery, radiation, and chemotherapy. Despite decades of work, however, overall survival in this group has been resistant to any substantial improvement. This review briefly details the evolution to the current standard of care for advanced NSCLC, advances in systemic therapy, and novel techniques (stereotactic body radiation therapy [SBRT], and transcervical extended mediastinal lymphadenectomy [TEMLA] or video-assisted mediastinal lymphadenectomy [VAMLA]) that have been used in localized NSCLC. The utility of these techniques in advanced stage therapy and potential methods of combining these novel techniques with systemic therapy to improve survival are discussed.
非小细胞肺癌（NSCLC）仍然是癌症死亡的主要原因。大多数患者就诊时已处于晚期（III-IV期）疾病。此类患者接受包括手术、放疗和化疗在内的多种治疗。然而，尽管经过数十年的努力，这组患者的总生存率仍未得到实质性改善。本综述简要详述了晚期NSCLC当前治疗标准的演变、全身治疗的进展以及已用于局限性NSCLC的新技术（立体定向体部放疗[SBRT]和经颈扩大纵隔淋巴结清扫术[TEMLA]或电视辅助纵隔淋巴结清扫术[VAMLA]）。讨论了这些技术在晚期治疗中的效用以及将这些新技术与全身治疗相结合以提高生存率的潜在方法。
